About Aptorum Group Limited
https://www.aptorumgroup.comAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments.
CEO
Chung Yuen Huen
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public December 18, 2018
Method of going public IPO
Full time employees 1
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-23 | Reverse | 1:10 |
| 2011-05-02 | Reverse | 1:3 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 5
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 0.00%
Total Number Of Holders 1
Showing Top 1 of 1
Market Cap $7.71 M
52w High $4.47
52w Low $0.69
P/E -3.03
Volume 37.17K
Outstanding Shares 7.14M
About Aptorum Group Limited
https://www.aptorumgroup.comAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $402.77K ▼ | $-441.78K ▲ | 0% | $-0.06 ▲ | $-402.77K ▲ |
| Q4-2024 | $0 | $928K ▼ | $-1.62M ▲ | 0% | $-0.29 ▲ | $-1.42M ▲ |
| Q2-2024 | $0 | $2.47M ▼ | $-2.64M ▼ | 0% | $-0.5 ▼ | $-2.33M ▼ |
| Q4-2023 | $0 ▼ | $3.54M ▼ | $2.66M ▲ | 0% ▲ | $0.51 ▲ | $2.74M ▲ |
| Q2-2023 | $431.38K | $5.87M | $-5.49M | -1.27K% | $-1.43 | $-5.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $2.76M ▲ | $18.1M ▲ | $4.34M ▼ | $23.13M ▲ |
| Q4-2024 | $874.24K ▲ | $16.13M ▼ | $4.35M ▼ | $21.13M ▼ |
| Q2-2024 | $783.09K ▼ | $17.7M ▼ | $4.53M ▼ | $22.65M ▼ |
| Q4-2023 | $2.01M ▲ | $20.64M ▲ | $5.26M ▲ | $24.85M ▲ |
| Q2-2023 | $340.31K | $14.41M | $1.63M | $21.84M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-1.62M ▲ | $89.73K ▲ | $0 ▼ | $1.43K ▲ | $91.15K ▲ | $89.73K ▲ |
| Q2-2024 | $-2.64M ▼ | $-1.28M ▲ | $58.62K ▼ | $0 ▼ | $-1.22M ▼ | $-1.28M ▲ |
| Q4-2023 | $2.66M ▲ | $-1.54M ▲ | $65.99K ▼ | $3.01M ▲ | $1.53M ▲ | $-1.54M ▲ |
| Q2-2023 | $-5.49M ▲ | $-6.24M ▼ | $558.78K ▲ | $1.14M ▼ | $-4.54M ▼ | $-6.24M ▼ |
| Q4-2022 | $-7.91M | $-5.46M | $-266.56K | $3.55M | $-2.18M | $-5.5M |
CEO
Chung Yuen Huen
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public December 18, 2018
Method of going public IPO
Full time employees 1
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-23 | Reverse | 1:10 |
| 2011-05-02 | Reverse | 1:3 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 5
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 0.00%
Total Number Of Holders 1
Showing Top 1 of 1